Skip to main content
Top
Published in: Annals of Surgical Oncology 2/2008

01-02-2008 | Gastrointestinal Oncology

Safety and Efficacy of Hyperthermic Intraperitoneal Chemoperfusion with High-Dose Oxaliplatin in Patients with Peritoneal Carcinomatosis

Authors: Wim P. Ceelen, MD, PhD, Marc Peeters, MD, PhD, Philippe Houtmeyers, MD, Christophe Breusegem, MD, Filip De Somer, Piet Pattyn, MD, PhD

Published in: Annals of Surgical Oncology | Issue 2/2008

Login to get access

Abstract

Background

Cytoreduction with hyperthermic intraperitoneal chemoperfusion (HIPEC) has an established role in selected patients with peritoneal carcinomatosis (PC). We analyzed the safety and efficacy of HIPEC using high-dose oxaliplatin, a cytotoxic agent commonly used in metastatic colorectal cancer and showing promising activity in ovarian cancer and mesothelioma.

Methods

Following complete cytoreduction, HIPEC was performed using 460 mg/m2 oxaliplatin in 5% dextrose for 30 min at a temperature of 41–42°C. Open perfusion (coliseum technique) was performed in all patients. Metabolic, electrolyte, and hemodynamic changes were recorded during chemoperfusion as well as postoperative morbidity, mortality, late toxicity, and survival.

Results

From July 2005 to January 2007, 52 patients were treated. Chemoperfusion with 5% dextrose resulted in temporary significant hyperglycemia, hyponatremia, and metabolic acidosis. Major morbidity developed in 24% of patients, while 30-day mortality did not occur. One patient developed unexplained repeated episodes of hemoperitoneum. Chemoperfusion with oxaliplatin resulted in mild hepatic toxicity evidenced by persistent elevation of glutamyl transferase and alkaline phosphatase 1 month after surgery. After a mean follow-up time of 14.5 months, nine patients died from disease progression. In colorectal cancer patients, actuarial overall survival was 80% at 1 year.

Conclusion

Cytoreduction with HIPEC using high-dose oxaliplatin leads to manageable metabolic and electrolyte disturbances and frequent mild hepatic toxicity without discernible impact on postoperative morbidity. Longer follow-up in a larger patient cohort will be required to assess the real risk of unexplained hemoperitoneum observed in one patient, and to establish the long-term effect on local relapse and survival.
Literature
1.
go back to reference Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006; 354:34–43PubMedCrossRef Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006; 354:34–43PubMedCrossRef
2.
go back to reference Flessner MF. The transport barrier in intraperitoneal therapy. Am J Physiol Renal Physiol 2005; 288:F433–F42PubMedCrossRef Flessner MF. The transport barrier in intraperitoneal therapy. Am J Physiol Renal Physiol 2005; 288:F433–F42PubMedCrossRef
3.
go back to reference Tannock IF, Lee CM, Tunggal JK, et al. Limited penetration of anticancer drugs through tumor tissue: A potential cause of resistance of solid tumors to chemotherapy. Clin Cancer Res 2002; 8:878–84PubMed Tannock IF, Lee CM, Tunggal JK, et al. Limited penetration of anticancer drugs through tumor tissue: A potential cause of resistance of solid tumors to chemotherapy. Clin Cancer Res 2002; 8:878–84PubMed
4.
go back to reference Verwaal VJ, van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003; 21:3737–43PubMedCrossRef Verwaal VJ, van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003; 21:3737–43PubMedCrossRef
5.
go back to reference Yan TD, Black D, Savady R, et al. Systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma. J Clin Oncol 2006; 24:4011–9PubMedCrossRef Yan TD, Black D, Savady R, et al. Systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma. J Clin Oncol 2006; 24:4011–9PubMedCrossRef
6.
go back to reference van Ruth S, Mathot RAA, Sparidans RW, et al. Population pharmacokinetics and pharmacodynamics of mitomycin during intraoperative hyperthermic intraperitoneal chemotherapy. Clin Pharmacokin 2004; 43:131–43CrossRef van Ruth S, Mathot RAA, Sparidans RW, et al. Population pharmacokinetics and pharmacodynamics of mitomycin during intraoperative hyperthermic intraperitoneal chemotherapy. Clin Pharmacokin 2004; 43:131–43CrossRef
7.
go back to reference Zeamari S, Floot B, Van der Vange N, et al. Pharmacokinetics and pharmacodynamics of cisplatin after Intraoperative Hyperthermic Intraperitoneal Chemoperfusion (HIPEC). Anticancer Res 2003; 23:1643–8PubMed Zeamari S, Floot B, Van der Vange N, et al. Pharmacokinetics and pharmacodynamics of cisplatin after Intraoperative Hyperthermic Intraperitoneal Chemoperfusion (HIPEC). Anticancer Res 2003; 23:1643–8PubMed
8.
go back to reference Los G, Vanvugt MJH, Pinedo HM. Response of peritoneal solid tumors after intraperitoneal chemohyperthermia treatment with cisplatin or carboplatin. Br J Cancer 1994; 69:235–41PubMed Los G, Vanvugt MJH, Pinedo HM. Response of peritoneal solid tumors after intraperitoneal chemohyperthermia treatment with cisplatin or carboplatin. Br J Cancer 1994; 69:235–41PubMed
9.
go back to reference Chau I, Cunningham D. Adjuvant therapy in colon cancer – what, when and how? Ann Oncol 2006; 17:1347–59PubMedCrossRef Chau I, Cunningham D. Adjuvant therapy in colon cancer – what, when and how? Ann Oncol 2006; 17:1347–59PubMedCrossRef
10.
go back to reference Elkas JC, Winter WE, Chernofsky MR, et al. A phase I trial of oxaliplatin and topotecan in recurrent ovarian carcinoma. Gynecol Oncol 2007; 104:422–7PubMedCrossRef Elkas JC, Winter WE, Chernofsky MR, et al. A phase I trial of oxaliplatin and topotecan in recurrent ovarian carcinoma. Gynecol Oncol 2007; 104:422–7PubMedCrossRef
11.
go back to reference Al-Batran SE, Atmaca A, Hegewisch-Becker S, et al. Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer. J Clin Oncol 2004; 22:658–63PubMedCrossRef Al-Batran SE, Atmaca A, Hegewisch-Becker S, et al. Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer. J Clin Oncol 2004; 22:658–63PubMedCrossRef
12.
go back to reference Fennell DA, Steele JPC, Shamash J, et al. Phase II trial of vinorelbine and oxaliplatin as first-line therapy in malignant pleural mesothelioma. Lung Cancer 2005; 47:277–81PubMedCrossRef Fennell DA, Steele JPC, Shamash J, et al. Phase II trial of vinorelbine and oxaliplatin as first-line therapy in malignant pleural mesothelioma. Lung Cancer 2005; 47:277–81PubMedCrossRef
13.
go back to reference Rietbroek RC, vandeVaart PJM, Haveman J, et al. Hyperthermia enhances the cytotoxicity and platinum-DNA adduct formation of lobaplatin and oxaliplatin in cultured SW 1573 cells. J Cancer Res Clin Oncol 1997; 123:6–12PubMedCrossRef Rietbroek RC, vandeVaart PJM, Haveman J, et al. Hyperthermia enhances the cytotoxicity and platinum-DNA adduct formation of lobaplatin and oxaliplatin in cultured SW 1573 cells. J Cancer Res Clin Oncol 1997; 123:6–12PubMedCrossRef
14.
go back to reference Pestieau SR, Belliveau JF, Griffin H, et al. Pharmacokinetics of intraperitoneal oxaliplatin: Experimental studies. J Surg Oncol 2001; 76:106–14PubMedCrossRef Pestieau SR, Belliveau JF, Griffin H, et al. Pharmacokinetics of intraperitoneal oxaliplatin: Experimental studies. J Surg Oncol 2001; 76:106–14PubMedCrossRef
15.
go back to reference Elias D, Bonnay A, Puizillou JM, et al. Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: Pharmacokinetics and tissue distribution. Ann Oncol 2002; 13:267–72PubMedCrossRef Elias D, Bonnay A, Puizillou JM, et al. Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: Pharmacokinetics and tissue distribution. Ann Oncol 2002; 13:267–72PubMedCrossRef
16.
go back to reference Jerremalm E, Hedeland M, Wallin I, et al. Oxaliplatin degradation in the presence of chloride: Identification and cytotoxicity of the monochloro monooxalato complex. Pharm Res 2004; 21:891–4PubMedCrossRef Jerremalm E, Hedeland M, Wallin I, et al. Oxaliplatin degradation in the presence of chloride: Identification and cytotoxicity of the monochloro monooxalato complex. Pharm Res 2004; 21:891–4PubMedCrossRef
17.
go back to reference Rubbia-Brandt L, Audard V, Sartoretti P, et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 2004; 15:460–6PubMedCrossRef Rubbia-Brandt L, Audard V, Sartoretti P, et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 2004; 15:460–6PubMedCrossRef
18.
go back to reference Arotcarena R, Cales V, Berthelemy P, et al. Severe sinusoidal lesions: A serious and overlooked complication of oxaliplatin-containing chemotherapy? Gastroenterol Clin Biol 2006; 30:1313–6PubMed Arotcarena R, Cales V, Berthelemy P, et al. Severe sinusoidal lesions: A serious and overlooked complication of oxaliplatin-containing chemotherapy? Gastroenterol Clin Biol 2006; 30:1313–6PubMed
20.
go back to reference Stephens AD, Alderman R, Chang D, et al. Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy using the Coliseum technique. Ann Surg Oncol 1999; 6:790–6PubMedCrossRef Stephens AD, Alderman R, Chang D, et al. Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy using the Coliseum technique. Ann Surg Oncol 1999; 6:790–6PubMedCrossRef
21.
go back to reference Colevas AD, Setser A. The NCI Common Terminology Criteria for Adverse Events (CTCAE) v 3.0 is the new standard for oncology clinical trials. J Clin Oncol 2004; 22:543S Colevas AD, Setser A. The NCI Common Terminology Criteria for Adverse Events (CTCAE) v 3.0 is the new standard for oncology clinical trials. J Clin Oncol 2004; 22:543S
22.
go back to reference Harnett P, Buck M, Beale P, et al. Phase II study of gemcitabine and oxaliplatin in patients with recurrent ovarian cancer: An Australian and New Zealand Gynaecological Oncology Group study. Int J Gynecol Cancer 2007; 17:359–66PubMedCrossRef Harnett P, Buck M, Beale P, et al. Phase II study of gemcitabine and oxaliplatin in patients with recurrent ovarian cancer: An Australian and New Zealand Gynaecological Oncology Group study. Int J Gynecol Cancer 2007; 17:359–66PubMedCrossRef
23.
go back to reference Ceelen WP, Pahlman L, Mahteme H. Pharmacodynamic aspects of Intraperitoneal Cytotoxic therapy. In: Ceelen WP (ed) Peritoneal carcinomatosis: A multidisciplinary approach. New York, Springer; 2007. pp 195–214 Ceelen WP, Pahlman L, Mahteme H. Pharmacodynamic aspects of Intraperitoneal Cytotoxic therapy. In: Ceelen WP (ed) Peritoneal carcinomatosis: A multidisciplinary approach. New York, Springer; 2007. pp 195–214
24.
go back to reference Elias D, El Otmany A, Bonnay M, et al. Human pharmacokinetic study of heated intraperitoneal oxaliplatin in increasingly hypotonic solutions after complete resection of peritoneal carcinomatosis. Oncology 2002; 63:346–52PubMedCrossRef Elias D, El Otmany A, Bonnay M, et al. Human pharmacokinetic study of heated intraperitoneal oxaliplatin in increasingly hypotonic solutions after complete resection of peritoneal carcinomatosis. Oncology 2002; 63:346–52PubMedCrossRef
25.
go back to reference Reed E. Cisplatin, Carboplatin, and Oxaliplatin. In: Chabner BA, Longo DL (eds) Cancer Chemotherapy & Biotherapy: Principles & Practices, 4th edition. Philadelphia: Lippincott Williams & Wilkins; 2006 Reed E. Cisplatin, Carboplatin, and Oxaliplatin. In: Chabner BA, Longo DL (eds) Cancer Chemotherapy & Biotherapy: Principles & Practices, 4th edition. Philadelphia: Lippincott Williams & Wilkins; 2006
26.
go back to reference Zorzi D, Laurent A, Pawlik TM, et al. Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases. Br J Surg 2007; 94:274–86PubMedCrossRef Zorzi D, Laurent A, Pawlik TM, et al. Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases. Br J Surg 2007; 94:274–86PubMedCrossRef
27.
go back to reference Levi F, Metzger G, Massari C, Milano G. Oxaliplatin: pharmacokinetics and chronopharmacological aspects. Clin Pharmacokinet 2000; 38:1–21PubMedCrossRef Levi F, Metzger G, Massari C, Milano G. Oxaliplatin: pharmacokinetics and chronopharmacological aspects. Clin Pharmacokinet 2000; 38:1–21PubMedCrossRef
Metadata
Title
Safety and Efficacy of Hyperthermic Intraperitoneal Chemoperfusion with High-Dose Oxaliplatin in Patients with Peritoneal Carcinomatosis
Authors
Wim P. Ceelen, MD, PhD
Marc Peeters, MD, PhD
Philippe Houtmeyers, MD
Christophe Breusegem, MD
Filip De Somer
Piet Pattyn, MD, PhD
Publication date
01-02-2008
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 2/2008
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-007-9648-5

Other articles of this Issue 2/2008

Annals of Surgical Oncology 2/2008 Go to the issue